Press Room

Press Release / Oct 09, 2008

Ivan Villax Traineeship Program

Loures, Portugal, October 9th, 2008 - Hovione announced today the signature of a protocol with The Budapest University of Technology and Economics (BME) regarding the Ivan Villax traineeship program. This ceremony will take place next October 10th, in Budapest.

Following the suggestion of the Portuguese – Hungarian Chamber of Commerce, and in order to pay tribute to the University where Hovione’s founder trained and graduated, the Company decided to institute a bursary program for two annual traineeships to enhance and develop the bonds between Portugal and Hungary. We will never forget that Ivan Villax believed in merit and competition therefore these traineeships will be awarded along the same set of criteria, said Mrs. Diane Villax, president of Hovione’s Board of Directors.

This traineeship program aims to create the conditions for an MSc organic chemistry student to work for a period of 4 to 6 months in an industrial R&D environment and to be part of a project team responsible for the development of a synthetic process for the preparation of an active pharmaceutical ingredient. The traineeship will include exposure to the preparation of the active ingredient under Good Manufacturing Practices for use in clinical trials or to its related analytical chemistry requirements. This will allow BME students to take part of a learning experience that will contribute to their knowledge and skills and will also help to create an important link between the two institutions.

 

About Hovione
Hovione is an international group specializing in the development and compliant manufacture of active pharmaceutical ingredients, serving exclusively the pharmaceutical industry. With a 50-year track record, Hovione offers advanced technologies as well as APIs for all drug delivery systems, from oral to injectable and from inhalation to topical applications. With FDA inspected plants in Europe, the Far East and the US, Hovione is committed to the highest levels of service and quality. Specializing in complex chemistry and in particle engineering, Hovione offers all services related to the development, manufacture and pre-formulation of both new chemical entities (NCEs) and existing APIs for off-patent products.

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026